Lilly's prasugrel on track for June approval

Lilly/Daiichi Sankyo's Effient (prasugrel) is granted a six-month priority review, giving the anti-clotting drug a June 26 action date, the companies announce Feb. 21. Prasugrel would be launched immediately after approval, according to Lilly, pitting the drug against Bristol-Myers Squibb'sPlavix (clopdiogrel). Prasugrel was compared head-to-head against clopidogrel in the pivotal TRITON trial:...